Shots:
Ultragenyx has entered into a definitive agreement to sell a Rare Pediatric Disease PRV for $210M, provide Ultragenyx with significant non-dilutive capital to advance therapies for rare & ultra-rare diseases
Rare Pediatric Disease PRV was received following FDA approval of Genglycos (pariglasgene brecaparvovec-opnr), the first treatment targeting the underlying cause of glycogen storage disease…
